Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iShares U.S. Healthcare ETF (NY: IYH )

60.44 +0.00 (+0.00%)
Streaming Delayed Price Updated: 9:57 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares U.S. Healthcare ETF

< Previous 1 2 Next >
Healthcare Sector Trying To Bounce Back
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector. 
Via Talk Markets
Topics ETFs Stocks / Equities
Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars?
Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as... 
Via Talk Markets
Topics ETFs Stocks / Equities
Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher. 
Via Benzinga
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH. 
Via Benzinga
Spotify, Vertiv Holdings And More: CNBC's 'Final Trades'
Joseph M. Terranova picked Spotify Technology, which reported better-than-expected fiscal fourth-quarter 2024 financial sales. 
Via Benzinga
US States Sue National Institutes Of Health Over $4 Billion Annual Cut In Biomedical Research Grant Budget
A federal judge halted NIH's plan to cap indirect grant costs at 15%, citing potential harm to research. A hearing is set for February 21. 
Via Benzinga
Goldman Sachs Predicts Gradual Recovery For Tools And Contract Research Sector In 2025, Stable Large Pharma Spending Key To Recovery
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely. 
Via Benzinga
World Health Organization Responds to Trump's Order, Reminds Decades of Successful Health Achievements
Trump signs an order to withdraw the U.S. from WHO, citing pandemic mismanagement, political influence, and inequitable funding, reigniting a past debate. 
Via Benzinga
Topics Government
Exposures Political
ETFs In Focus Post UnitedHealth's Mixed Q4 Results
UnitedHealth Group, the largest U.S. health insurer, reported mixed fourth-quarter 2024 results. Shares of the stock dropped nearly 6% on the day following the results. This put various ETFs in the... 
Via Talk Markets
Topics ETFs Stocks / Equities
Intuitive Surgical Stock Hits All-Time High After Prelim Q4 Results Outpace Expectations: Retail Goes All In
Intuitive said worldwide da Vinci procedure volumes grew 18% in Q4 and 17% in 2024, driven by U.S. general surgery and international cancer procedures. 
Via Stocktwits
Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%
Billionaire Stanley Druckenmiller's latest large wager on biotech company Natera Inc has paid off, with his stake now exceeding $575 million. 
Via Benzinga
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. 
Via Benzinga
Topics ETFs
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency. 
Via Benzinga
Topics Government
Exposures Political Product Safety
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
Deere, Amgen, Copart And More: CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Jim Lebenthal of Cerity Partners named Deere & Company as his final trade. 
Via Benzinga
Defensive ETFs Shine Amid A Rough Start To September
U.S. stocks started September on a dismal note on economic slowdown concerns following weak data, which shows that manufacturing shrank again in August. 
Via Talk Markets
Topics ETFs
AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Via Benzinga
Delta Air Lines, Interactive Brokers And More: CNBC's 'Final Trades'
Delta shares fell 3.5% to close at $43.83 on Monday. It struggles to recover from the cyber outage that impacted operations last week. 
Via Benzinga
Healthcare Investors Bet On Easier Medicare Rules Under Potential Trump Administration
Investors expect Trump to ease Medicare Advantage regulations if he wins another term. This could lead to renewed merger talks among health insurers. 
Via Benzinga
Topics Government
Exposures Political
Want to Earn More in the Stock Market With Less Effort? Try This Simple Strategy
You don't need to be a stock market expert to earn above-average returns. 
Via The Motley Fool
'Barbarism:' AOC Unleashes Fury On US Healthcare System As People Are 'Choosing Between Medicine And Rent'
America has one of the highest healthcare costs in the world, with healthcare spending hitting $4.5 trillion in 2022. 
Via Benzinga
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... 
Via Talk Markets
Topics ETFs
Target, Apollo Global Management, Las Vegas Sands And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors named Apollo Global Management, Inc. 
Via Benzinga
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE: SHAK) 
Via Benzinga
Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy
In a recent development in the health insurance sector, Cigna Corporation (NYSE: CI) has withdrawn from its proposed merger with Humana Inc. (NYSE: 
Via Benzinga
Humana, Comerica, Cleveland-Cliffs, And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Shannon Saccocia of Boston Private named iShares U.S. 
Via Benzinga
Cisco, Burlington Stores, Broadcom And More On CNBC's 'Final Trades'
It has been "a really tough year" for the healthcare sector. That's according to Shannon Saccocia of Boston Private, who appeared on CNBC’s "Halftime Report Final Trades." 
Via Benzinga
Lab-Developed Tests Under FDA Scrutiny: What It Means For Startups
A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups advance various tests to detect diseases sooner and personalize treatments. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.